HOME >> MEDICINE >> NEWS
European commission grants "orphan" status for new acute myeloid leukaemia treatment

Wyeth-Ayerst Pharmaceuticals, the pharmaceutical division of American Home Products Corporation (NYSE:AHP),announced today that the European Commission has designated Mylotarg(gemtuzumab ozogamicin)as an "orphan medicinal product." The Commission decision follows a positive opinion adopted on 13 September 2000 by the Committee on Orphan Medicinal Products (COMP) of the European Agency for the Evaluation of Medicinal Products (EMEA).

"We anticipate that Mylotarg will become an important treatment option for European patients aged 60 and over with CD33-positive relapsed acute myeloid leukaemia (AML)," says L. Patrick Gage, Ph.D., President, Wyeth-Ayerst Research. "Its mechanism of action focuses on using antibody-antigen specificity to target delivery of potent chemotherapy to myeloid leukaemic cells. This compound represents the first product from Wyeth's promising oncology pipeline."

As a designated orphan medicinal product, Mylotarg will have access to the Commission's "centralised" procedure for assessment of the marketing authorisation application. Orphan medicinal products are intended to treat patients with rare life-threatening or very serious diseases for which no satisfactory method of treatment exists or where the product will be of significant benefit.

Orphan medicinal products do not automatically qualify for approval under "exceptional circumstances," but companies that sponsor orphan products receive incentives for bringing these products to the market and to the patient. Such incentives include the possibility of protocol assistance from the EMEA and fee reductions for all types of centralised marketing authorisation evaluation activities. If approved by the EMEA, Mylotarg would be the first product available in Europe from a new class of anticancer therapy known as "antibody-targeted chemotherapy." Mylotarg utilizes a patented linker technology with a novel potent anti-tumor antibiotic, calicheamicin.

Mylotarg is being develo
'"/>

Contact: Roseann Ward
roseann.ward@ketchumcomms.co.uk
44-0-207-465-8752
Ketchum
14-Nov-2000


Page: 1 2 3

Related medicine news :

1. ESC releases the first European Guidelines on Percutaneous Coronary Interventions (PCI)
2. The European Society of Cardiology launches Women at Heart
3. Use of potentially inappropriate medications among elderly common in some European countries
4. European folic acid policies are not effective enough
5. New European cancer figures for 2004 major efforts needed against the big four killers
6. Third of European cancer patients use complementary and alternative therapies
7. A new service from the European Patent Office
8. European study highlights persistent 3 decade increase in childhood cancer incidence
9. European nations urged to ratify international treaty on tobacco control
10. Increased investment in radiotherapy will improve cure rates for European cancer patients
11. ESA looking for more European women to volunteer for WISE bed-rest study in Toulouse next year

Post Your Comments:
(Date:5/24/2015)... Lake Orion, Clarkston, Metamora, Michigan (PRWEB) May 24, 2015 ... sees many patients for concerns about hair loss. Although ... it is clear that there are environmental factors such ... hormone that can contribute. Since they offer a comprehensive ... of the peri and post-menopausal woman, they can help ...
(Date:5/24/2015)... NH (PRWEB) May 24, 2015 ... leather, launches “InkGard™ Plus” – a classic, rugged ... the polymer allowing difficult stains, including ink, to ... 16 different colors suitable for corporate, healthcare, hospitality ... in line with EnviroLeather’s goal of developing products ...
(Date:5/24/2015)... Arizona (PRWEB) May 24, 2015 ... former Millennial Media strategy executive Jay Krihak as ... Medicx looks to ramp up its expertise and ... of the Pharmaceutical and Health sectors. , Krihak ... tech executive. Most recently, Krihak led sales planning ...
(Date:5/23/2015)... D.C. (PRWEB) May 23, 2015 On ... of powers of a youngster's yogic power learned through ... Sri Nithyananda Swami in Bangalore, India. , Yogamaatha, a ... more than 50 high profile professionals attending the 2015 ... by reading fluently -- blindfolded. , In a ...
(Date:5/23/2015)... On May 16, the team at Farrell’s eXtreme ... mud obstacle run that raised funds for multiple sclerosis. ... the reason we participated was to support people living with ... eXtreme Bodyshaping. “One-hundred percent of the funds raised go to ... not only attended by eXtreme Bodyshaping staff, but members of ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Treats Menopausal Hair Loss 2Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Medicx Media Solutions Expands Executive Team 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2
(Date:5/22/2015)... /CNW/ - More than fifty years ago, Thalidomide was approved ... expectant mothers. Tragically, Thalidomide caused serious and permanent physical and ... Support has been provided to survivors over the years from ... in 1991 and settlements from drug companies. ... to provide support, we have a clear moral obligation to ...
(Date:5/22/2015)... May 22, 2015 The Assistance Fund announces ... program provides financial assistance for copay to individuals diagnosed ... announce the addition of the Melanoma Copay Assistance Program ... McGreevy , executive director. "With each additional program we ... a world where no one is denied access to ...
(Date:5/22/2015)... FORT WORTH, Texas , May 22, 2015 ... at $58.4 million in 2014 and is estimated to reach ... 2014 to 2019. Browse through the TOC of ... trends and segments, with the help of various tables and ... buyers will receive 10% customization on this report.   ...
Breaking Medicine Technology:Statement from Minister Ambrose on Thalidomide 2Statement from Minister Ambrose on Thalidomide 3The Assistance Fund Adds Melanoma Assistance Program 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3
Cached News: